Drug Trial Radar · NCT07921966
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Oct 16, 2026
Primary completion
Jan 14, 2027
Study completion Jan 14, 2027
Sponsor
- Lead sponsor
- Neurelis, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, 5-period, 2-sequence, single ascending dose study designed to assess the pharmacokinetics, dose proportionality, safety, and tolerability of NRL-1004 (olanzapine nasal spray), and to assess the relative bioavailability of NRL-1004, compared to olanzapine intramuscular injection (ZYPREXA IM), in healthy adult participants. The study will be conducted in a single clinical research unit (CRU).
Conditions
- Healthy Adult Participants
Interventions
NRL-1004 2.5 mgDrug
Olanzapine nasal spray
ZYPREXA IM 10mgDrug
Olanzapine IM injection
NRL-1004 5.0 mgDrug
Olanzapine nasal spray
NRL-1004 7.5 mgDrug
Olanzapine nasal spray
NRL-1004 10.0 mgDrug
Olanzapine nasal spray
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
- Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
- Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
- Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
- Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
- Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
- Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
- Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
- Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
- Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
- Pharmacokinetic parameters of olanzapine in plasmaTime frame: Time zero to 14 days postdose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.